Direkt zum Inhalt
Merck
  • Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development.

Differential expression of SV2A in hippocampal glutamatergic and GABAergic terminals during postnatal development.

Brain research (2019-03-25)
América Vanoye-Carlo, Gisela Gómez-Lira
ZUSAMMENFASSUNG

The function of synaptic vesicle protein 2A (SV2A) has not been clearly identified, although it has an essential role in normal neurotransmission. Changes in SV2A expression have been linked to several diseases that could implicate an imbalance between excitation and inhibition, such as epilepsy. Although it is known that SV2A expression is necessary for survival, SV2A expression and its relationship with γ-aminobutyric acid (GABA) and glutamate neurotransmitter systems along development has not been addressed. This report follows SV2A expression levels in the rat hippocampus and their association with glutamatergic and GABAergic terminals along postnatal development. Total SV2A expression was assessed by real time PCR and western blot, while immunofluorescence was used to identify SV2A protein in the different hippocampal layers and its co-localization with GABA or glutamate vesicular transporters. SV2A was dynamically regulated along development and its association with GABA or glutamate transporters varied in the different hippocampal layers. In the principal cells layers (granular and pyramidal), SV2A protein was preferentially localized to GABAergic terminals, while in the hilus and stratum lucidum SV2A was associated mainly to glutamatergic terminals. Although SV2A was ubiquitously expressed in the entire hippocampus, it established a differential association with excitatory or inhibitory terminals, which could contribute to the maturation of excitatory/inhibitory balance.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
KiCqStart® One-Step Probe RT-qPCR ReadyMix, for Bio-Rad, Cepheid, Eppendorf, Illumina, Corbett, and Roche systems